2022年12月15日

頂級投資者財團包括新投資者拱Venture Partners,蓋茨前沿,貝佐斯探險,依賴數字醫療有限,Greenoaks,校友企業,摩爾戰略投資和項目X,在遵循現有投資者的參與包括科斯拉風險投資公司,腦科學投資者,混血兒,Forepont Capital Partners ID8投資,盛大集團和墨爾本大學。基金將加速產品開發,促進一個關鍵的臨床試驗的畢業典禮,並推進同步向first-in-class BCI市場批準治療癱瘓。下載加載媒體播放器…Stentrode™中植入大腦運動皮層通過頸靜脈血管內手術。Stentrode™中植入大腦運動皮層通過頸靜脈血管內手術。東部標準時間2022年12月15日喂飼是紐約——(業務線)——同步,血管內腦-機接口(BCI)公司,今天宣布一個超額認購7500萬美元的C融資輪拱合資企業的合作夥伴。蓋茨前沿,貝佐斯探險,依賴數字醫療有限,Greenoaks,校友企業,摩爾戰略投資,項目X作為新的更多的投資者加入拱。現有的投資者,包括科斯拉風險投資公司,腦科學投資者,混血兒,Forepont Capital Partners ID8投資,盛大集團和墨爾本大學參加了一輪。C係列融資帶來總量自《盜夢空間》提高到1.45億美元。資金將加快發展同步的第一個平台產品(同步開關™BCI),並啟動一個關鍵的臨床試驗。 Ari Nowacek from ARCH Venture Partners will join Synchron’s Board of Directors, and ARCH Co-Founder and Managing Director Robert Nelsen will join as Board Observer. “We have an opportunity to deliver a first-in-class commercial BCI. The problem of paralysis is much larger than people realize. 100 million people worldwide have upper limb impairment,” said Tom Oxley, M.D., Ph.D., CEO & Founder, Synchron. “We are extremely excited to work with ARCH and this world-class syndicate to bring this technology to the people who need it.” “At ARCH, our approach has always been to pair great science and technology with remarkable teams to build disruptive companies. The technology we witnessed at Synchron is helping people with previously untreatable conditions regain connection to the world. It is an exciting time for neurotechnology,” said ARCH Co-Founder and Managing Director Robert Nelsen. The Synchron Switch™ brain computer interface is implanted in the blood vessel on the surface of the motor cortex of the brain via the jugular vein, through a minimally-invasive endovascular procedure. Once implanted, it is designed to detect and wirelessly transmit motor intent out of the brain, restoring a capability for severely paralyzed patients to control personal devices with hands-free point-and-click. Synchron has an ongoing US clinical trial, COMMAND, that assesses the impact on daily tasks such as texting, emailing, online shopping, and telehealth services. The FDA granted Breakthrough Device designation to Synchron in August 2020 and an Investigational Device Exemption in July 2021. The first US patient was implanted in July 2022 at Mount Sinai in New York. View Synchron CEO 2022 TED Talk , “A brain implant that turns your thoughts into text.” About Synchron Synchron is a clinical-stage endovascular brain computer interface (BCI) company. Since 2012, the company has been developing a BCI platform that avoids the need for open brain surgery by using a minimally-invasive procedure. The Synchron Switch™ BCI received FDA Breakthrough Device Designation in 2020, and is currently in human clinical trials in the US and Australia. Synchron has been published in multiple peer-reviewed journals including Nature Biotechnology, Nature Biomedical Engineering and JNIS. Synchron is based in Brooklyn, New York with R&D facilities in Melbourne, Australia. For more information, visit www.synchron.com . Follow us on Twitter @synchroninc . Contacts